Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

An International, Multicentered, EvidenceBased Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome.

Adler A, Novelli V, Amin AS, Abiusi E, Care M, Nannenberg EA, Feilotter H, Amenta S, Mazza D, Bikker H, Sturm AC, Garcia J, Ackerman MJ, Hershberger RE, Perez MV, Zareba W, Ware JS, Wilde AAM, Gollob MH.

Circulation. 2020 Jan 27. doi: 10.1161/CIRCULATIONAHA.119.043132. [Epub ahead of print] No abstract available.

PMID:
31983240
2.

Inter-laboratory proficiency testing scheme for tumour next-generation sequencing in Ontario: a pilot study.

Spence T, Stickle N, Yu C, Chow H, Feilotter H, Lo B, McCready E, Sadikovic B, Siu LL, Bedard PL, Stockley TL.

Curr Oncol. 2019 Dec;26(6):e717-e732. doi: 10.3747/co.26.5379. Epub 2019 Dec 1.

3.

OCTANE (Ontario-wide Cancer Targeted Nucleic Acid Evaluation): a platform for intraprovincial, national, and international clinical data-sharing.

Malone ER, Saleh RR, Yu C, Ahmed L, Pugh T, Torchia J, Bartlett J, Virtanen C, Hotte SJ, Hilton J, Welch S, Robinson A, McCready E, Lo B, Sadikovic B, Feilotter H, Hanna TP, Kamel-Reid S, Stockley TL, Siu LL, Bedard PL.

Curr Oncol. 2019 Oct;26(5):e618-e623. doi: 10.3747/co.26.5235. Epub 2019 Oct 1.

4.

CCMG practice guideline: laboratory guidelines for next-generation sequencing.

Hume S, Nelson TN, Speevak M, McCready E, Agatep R, Feilotter H, Parboosingh J, Stavropoulos DJ, Taylor S, Stockley TL; Canadian College of Medical Geneticists (CCMG).

J Med Genet. 2019 Dec;56(12):792-800. doi: 10.1136/jmedgenet-2019-106152. Epub 2019 Jul 12.

5.

Implementation of an NGS-based sequencing and gene fusion panel for clinical screening of patients with suspected hematologic malignancies.

Levy MA, Santos S, Kerkhof J, Stuart A, Aref-Eshghi E, Guo F, Hedley B, Wong H, Rauh M, Feilotter H, Berardi P, Semenuk L, Yang P, Knoll J, Ainsworth P, McLachlin CM, Chin-Yee I, Kovacs M, Deotare U, Lazo-Langner A, Hsia C, Keeney M, Xenocostas A, Howlett C, Lin H, Sadikovic B.

Eur J Haematol. 2019 Sep;103(3):178-189. doi: 10.1111/ejh.13272. Epub 2019 Jul 30.

PMID:
31177553
6.

Plasma microRNA expression levels and their targeted pathways in patients with major depressive disorder who are responsive to duloxetine treatment.

Kim HK, Tyryshkin K, Elmi N, Dharsee M, Evans KR, Good J, Javadi M, McCormack S, Vaccarino AL, Zhang X, Andreazza AC, Feilotter H.

J Psychiatr Res. 2019 Mar;110:38-44. doi: 10.1016/j.jpsychires.2018.12.007. Epub 2018 Dec 8.

PMID:
30580082
7.

Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study.

Vaughn CP, Costa JL, Feilotter HE, Petraroli R, Bagai V, Rachiglio AM, Marino FZ, Tops B, Kurth HM, Sakai K, Mafficini A, Bastien RRL, Reiman A, Le Corre D, Boag A, Crocker S, Bihl M, Hirschmann A, Scarpa A, Machado JC, Blons H, Sheils O, Bramlett K, Ligtenberg MJL, Cree IA, Normanno N, Nishio K, Laurent-Puig P.

BMC Cancer. 2018 Aug 16;18(1):828. doi: 10.1186/s12885-018-4736-4.

8.

Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.

Bradbury PA, Morris DG, Nicholas G, Tu D, Tehfe M, Goffin JR, Shepherd FA, Gregg RW, Rothenstein J, Lee C, Kuruvilla S, Keith BD, Torri V, Blais N, Hao D, Korpanty GJ, Goss G, Melosky BL, Mates M, Leighl N, Ayoub JP, Sederias J, Feilotter H, Seymour L, Laurie SA.

Lung Cancer. 2018 Jun;120:142-148. doi: 10.1016/j.lungcan.2018.03.005. Epub 2018 Mar 9.

PMID:
29748010
9.

A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial.

Jonker DJ, Tang PA, Kennecke H, Welch SA, Cripps MC, Asmis T, Chalchal H, Tomiak A, Lim H, Ko YJ, Chen EX, Alcindor T, Goffin JR, Korpanty GJ, Feilotter H, Tsao MS, Theis A, Tu D, Seymour L.

Clin Colorectal Cancer. 2018 Sep;17(3):231-239.e7. doi: 10.1016/j.clcc.2018.03.001. Epub 2018 Mar 8.

PMID:
29653857
10.

A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209.

Eigl BJ, Chi K, Tu D, Hotte SJ, Winquist E, Booth CM, Canil C, Potvin K, Gregg R, North S, Zulfiqar M, Ellard S, Ruether JD, Le L, Kakumanu AS, Salim M, Allan AL, Feilotter H, Theis A, Seymour L.

Oncotarget. 2018 Jan 17;9(8):8155-8164. doi: 10.18632/oncotarget.24263. eCollection 2018 Jan 30.

11.

Familial PDGFRA-mutation syndrome: somatic and gastrointestinal phenotype.

Manley PN, Abu-Abed S, Kirsch R, Hawrysh A, Perrier N, Feilotter H, Pollett A, Riddell RH, Hookey L, Walia JS.

Hum Pathol. 2018 Jun;76:52-57. doi: 10.1016/j.humpath.2018.02.014. Epub 2018 Feb 25.

PMID:
29486293
12.

Examining redox modulation pathways in the post-mortem frontal cortex in patients with bipolar disorder through data mining of microRNA expression datasets.

Kim HK, Tyryshkin K, Elmi N, Feilotter H, Andreazza AC.

J Psychiatr Res. 2018 Apr;99:39-49. doi: 10.1016/j.jpsychires.2018.01.011. Epub 2018 Jan 31.

PMID:
29407286
13.

A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.

Bernstein V, Ellard SL, Dent SF, Tu D, Mates M, Dhesy-Thind SK, Panasci L, Gelmon KA, Salim M, Song X, Clemons M, Ksienski D, Verma S, Simmons C, Lui H, Chi K, Feilotter H, Hagerman LJ, Seymour L.

Breast Cancer Res Treat. 2018 Jan;167(2):485-493. doi: 10.1007/s10549-017-4538-4. Epub 2017 Oct 13.

PMID:
29027598
14.

Data sharing as a national quality improvement program: reporting on BRCA1 and BRCA2 variant-interpretation comparisons through the Canadian Open Genetics Repository (COGR).

Lebo MS, Zakoor KR, Chun K, Speevak MD, Waye JS, McCready E, Parboosingh JS, Lamont RE, Feilotter H, Bosdet I, Tucker T, Young S, Karsan A, Charames GS, Agatep R, Spriggs EL, Chisholm C, Vasli N, Daoud H, Jarinova O, Tomaszewski R, Hume S, Taylor S, Akbari MR, Lerner-Ellis J; Canadian Open Genetics Repository Working Group.

Genet Med. 2018 Mar;20(3):294-302. doi: 10.1038/gim.2017.80. Epub 2017 Jul 20.

PMID:
28726806
15.

MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes.

Lopez JP, Fiori LM, Cruceanu C, Lin R, Labonte B, Cates HM, Heller EA, Vialou V, Ku SM, Gerald C, Han MH, Foster J, Frey BN, Soares CN, Müller DJ, Farzan F, Leri F, MacQueen GM, Feilotter H, Tyryshkin K, Evans KR, Giacobbe P, Blier P, Lam RW, Milev R, Parikh SV, Rotzinger S, Strother SC, Lewis CM, Aitchison KJ, Wittenberg GM, Mechawar N, Nestler EJ, Uher R, Kennedy SH, Turecki G.

Nat Commun. 2017 May 22;8:15497. doi: 10.1038/ncomms15497.

16.

Reduction in membranous immunohistochemical staining for the intracellular domain of epithelial cell adhesion molecule correlates with poor patient outcome in primary colorectal adenocarcinoma.

Wang A, Ramjeesingh R, Chen CH, Hurlbut D, Hammad N, Mulligan LM, Nicol C, Feilotter HE, Davey S.

Curr Oncol. 2016 Jun;23(3):e171-8. doi: 10.3747/co.23.3028. Epub 2016 Jun 9.

17.

Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.

Lam RW, Milev R, Rotzinger S, Andreazza AC, Blier P, Brenner C, Daskalakis ZJ, Dharsee M, Downar J, Evans KR, Farzan F, Foster JA, Frey BN, Geraci J, Giacobbe P, Feilotter HE, Hall GB, Harkness KL, Hassel S, Ismail Z, Leri F, Liotti M, MacQueen GM, McAndrews MP, Minuzzi L, Müller DJ, Parikh SV, Placenza FM, Quilty LC, Ravindran AV, Salomons TV, Soares CN, Strother SC, Turecki G, Vaccarino AL, Vila-Rodriguez F, Kennedy SH; CAN-BIND Investigator Team.

BMC Psychiatry. 2016 Apr 16;16:105. doi: 10.1186/s12888-016-0785-x.

18.

Eligibility Criteria and Genetic Testing Results from a High-Risk Cohort for Hereditary Breast and Ovarian Cancer Syndrome in Southeastern Ontario.

Dos Santos Vidal R, Hawrysh A, Walia JS, Davey S, Feilotter H.

J Mol Diagn. 2016 May;18(3):362-369. doi: 10.1016/j.jmoldx.2015.11.007.

19.

Roles for miR-375 in Neuroendocrine Differentiation and Tumor Suppression via Notch Pathway Suppression in Merkel Cell Carcinoma.

Abraham KJ, Zhang X, Vidal R, Paré GC, Feilotter HE, Tron VA.

Am J Pathol. 2016 Apr;186(4):1025-35. doi: 10.1016/j.ajpath.2015.11.020. Epub 2016 Feb 11.

20.

ATM gene mutations in sporadic breast cancer patients from Brazil.

Mangone FR, Miracca EC, Feilotter HE, Mulligan LM, Nagai MA.

Springerplus. 2015 Jan 15;4:23. doi: 10.1186/s40064-015-0787-z. eCollection 2015.

21.

BRCA1 haploinsufficiency leads to altered expression of genes involved in cellular proliferation and development.

Feilotter HE, Michel C, Uy P, Bathurst L, Davey S.

PLoS One. 2014 Jun 20;9(6):e100068. doi: 10.1371/journal.pone.0100068. eCollection 2014.

22.

Inactivation of the CDKN2A tumor-suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome.

Alhejaily A, Day AG, Feilotter HE, Baetz T, Lebrun DP.

Clin Cancer Res. 2014 Mar 15;20(6):1676-86. doi: 10.1158/1078-0432.CCR-13-2175. Epub 2014 Jan 21.

23.

Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.

Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, Weberpals J, Childs T, Bryson P, Dharsee M, Evans K, Feilotter HE, Park PC, Squire JA.

BMC Cancer. 2013 Nov 16;13:549. doi: 10.1186/1471-2407-13-549.

24.

Exploring high dimensional data with Butterfly: a novel classification algorithm based on discrete dynamical systems.

Geraci J, Dharsee M, Nuin P, Haslehurst A, Koti M, Feilotter HE, Evans K.

Bioinformatics. 2014 Mar 1;30(5):712-8. doi: 10.1093/bioinformatics/btt602. Epub 2013 Oct 21.

PMID:
24149051
25.

Multicolor microRNA FISH effectively differentiates tumor types.

Renwick N, Cekan P, Masry PA, McGeary SE, Miller JB, Hafner M, Li Z, Mihailovic A, Morozov P, Brown M, Gogakos T, Mobin MB, Snorrason EL, Feilotter HE, Zhang X, Perlis CS, Wu H, Suárez-Fariñas M, Feng H, Shuda M, Moore PS, Tron VA, Chang Y, Tuschl T.

J Clin Invest. 2013 Jun;123(6):2694-702.

26.

The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction.

Kennedy SH, Downar J, Evans KR, Feilotter H, Lam RW, MacQueen GM, Milev R, Parikh SV, Rotzinger S, Soares C.

Curr Pharm Des. 2012;18(36):5976-89.

PMID:
22681173
27.

Stathmin 1 is a potential novel oncogene in melanoma.

Chen J, Abi-Daoud M, Wang A, Yang X, Zhang X, Feilotter HE, Tron VA.

Oncogene. 2013 Mar 7;32(10):1330-7. doi: 10.1038/onc.2012.141. Epub 2012 Jun 4.

PMID:
22665054
28.

A pilot study of urinary microRNA as a biomarker for urothelial cancer.

Snowdon J, Boag S, Feilotter H, Izard J, Siemens DR.

Can Urol Assoc J. 2013 Jan-Feb;7(1-2):28-32. doi: 10.5489/cuaj.11115.

29.

EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer.

Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, Davey S, Squire J, Park PC, Feilotter H.

BMC Cancer. 2012 Mar 19;12:91. doi: 10.1186/1471-2407-12-91.

30.

The microRNA-200 family is upregulated in endometrial carcinoma.

Snowdon J, Zhang X, Childs T, Tron VA, Feilotter H.

PLoS One. 2011;6(8):e22828. doi: 10.1371/journal.pone.0022828. Epub 2011 Aug 29.

31.

miR-193b Regulates Mcl-1 in Melanoma.

Chen J, Zhang X, Lentz C, Abi-Daoud M, Paré GC, Yang X, Feilotter HE, Tron VA.

Am J Pathol. 2011 Nov;179(5):2162-8. doi: 10.1016/j.ajpath.2011.07.010. Epub 2011 Sep 3.

32.

Differential expression of cell-cycle regulatory proteins defines distinct classes of follicular lymphoma.

Alhejaily A, Wood B, Foster CJ, Farmer PL, Gilks CB, Brettschneider J, Day AG, Feilotter HE, Baetz T, LeBrun DP.

Hum Pathol. 2011 Jul;42(7):972-82. doi: 10.1016/j.humpath.2010.10.011. Epub 2011 Feb 2.

PMID:
21292305
33.

Immunohistochemical Assessment of Expression of Centromere Protein-A (CENPA) in Human Invasive Breast Cancer.

Rajput AB, Hu N, Varma S, Chen CH, Ding K, Park PC, Chapman JA, Sengupta SK, Madarnas Y, Elliott BE, Feilotter HE.

Cancers (Basel). 2011 Dec 6;3(4):4212-27. doi: 10.3390/cancers3044212.

34.

MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma.

Chen J, Feilotter HE, Paré GC, Zhang X, Pemberton JG, Garady C, Lai D, Yang X, Tron VA.

Am J Pathol. 2010 May;176(5):2520-9. doi: 10.2353/ajpath.2010.091061. Epub 2010 Mar 19.

35.

An array-based analysis of microRNA expression comparing matched frozen and formalin-fixed paraffin-embedded human tissue samples.

Zhang X, Chen J, Radcliffe T, Lebrun DP, Tron VA, Feilotter H.

J Mol Diagn. 2008 Nov;10(6):513-9. doi: 10.2353/jmoldx.2008.080077. Epub 2008 Oct 2.

36.

Primary cardiac lymphoma: molecular cytogenetic characterization of a rare entity.

Schell AJ, Xu Y, Baetz T, Harrison K, Ropchan G, LeBrun D, Feilotter H.

Cardiovasc Pathol. 2009 Mar-Apr;18(2):92-9. doi: 10.1016/j.carpath.2008.01.002. Epub 2008 Mar 6.

PMID:
18402841
37.

Predicting outcome in follicular lymphoma by using interactive gene pairs.

LeBrun D, Baetz T, Foster C, Farmer P, Sidhu R, Guo H, Harrison K, Somogyi R, Greller LD, Feilotter H.

Clin Cancer Res. 2008 Jan 15;14(2):478-87. doi: 10.1158/1078-0432.CCR-07-1720.

38.

DNA microarray analysis for the detection of mutations in hemophilia A.

Berber E, Leggo J, Brown C, Berber E, Gallo N, Feilotter H, Lillicrap D.

J Thromb Haemost. 2006 Aug;4(8):1756-62.

39.

Microarrays in veterinary diagnostics.

Feilotter HE.

Anim Health Res Rev. 2004 Dec;5(2):249-55. Review.

PMID:
15984334
40.

Alternatively spliced, truncated human BRCA2 isoforms contain a novel coding exon.

Speevak MD, Young SS, Feilotter H, Ainsworth P.

Eur J Hum Genet. 2003 Dec;11(12):951-4.

41.

Individual and family characteristics associated with protein truncating BRCA1 and BRCA2 mutations in an Ontario population based series from the Cooperative Family Registry for Breast Cancer Studies.

Ozcelik H, Knight JA, Glendon G, Yazici H, Carson N, Ainsworth PJ, Taylor SA, Feilotter H, Carter RF, Boyd NF, Andrulis IL; Ontario Cancer Genetics Network.

J Med Genet. 2003 Aug;40(8):e91. No abstract available.

42.

Expression of hsp16 in response to nucleotide depletion is regulated via the spc1 MAPK pathway in Schizosaccharomyces pombe.

Taricani L, Feilotter HE, Weaver C, Young PG.

Nucleic Acids Res. 2001 Jul 15;29(14):3030-40.

43.

Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma.

Feilotter HE, Coulon V, McVeigh JL, Boag AH, Dorion-Bonnet F, Duboué B, Latham WC, Eng C, Mulligan LM, Longy M.

Br J Cancer. 1999 Feb;79(5-6):718-23.

44.

Analysis of PTEN and the 10q23 region in primary prostate carcinomas.

Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM.

Oncogene. 1998 Apr 2;16(13):1743-8.

45.

Evidence for linkage of bipolar disorder to chromosome 18 with a parent-of-origin effect.

Stine OC, Xu J, Koskela R, McMahon FJ, Gschwend M, Friddle C, Clark CD, McInnis MG, Simpson SG, Breschel TS, Vishio E, Riskin K, Feilotter H, Chen E, Shen S, Folstein S, Meyers DA, Botstein D, Marr TG, DePaulo JR.

Am J Hum Genet. 1995 Dec;57(6):1384-94.

46.

Construction of an improved host strain for two hybrid screening.

Feilotter HE, Hannon GJ, Ruddell CJ, Beach D.

Nucleic Acids Res. 1994 Apr 25;22(8):1502-3. No abstract available.

47.

Regulation of the G2-mitosis transition.

Feilotter H, Lingner C, Rowley R, Young PG.

Biochem Cell Biol. 1992 Oct-Nov;70(10-11):954-71. Review.

PMID:
1297355
48.

Genetic and molecular analysis of cdr1/nim1 in Schizosaccharomyces pombe.

Feilotter H, Nurse P, Young PG.

Genetics. 1991 Feb;127(2):309-18.

49.

stf1: a new suppressor of the mitotic control gene, cdc25, in Schizosaccharomyces pombe.

Hudson JD, Feilotter H, Lingner C, Rowley R, Young PG.

Cold Spring Harb Symp Quant Biol. 1991;56:599-604.

PMID:
1819509
50.

Supplemental Content

Loading ...
Support Center